JEITO

Five months after the exit of our portfolio company Hi-Bio to Biogen, we are excited to share that the company has hit another value-creation milestone. Felzartamab, Biogen's investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for the treatment of severe immune-mediated diseases. The FDA grants BTD to drug candidates that address serious or life-threatening conditions and have preliminary clinical evidence demonstrating the potential to provide substantial improvements over existing therapies. This marks another step in bringing this promising drug candidate to patients, once again highlighting Jeito's ability to source high-quality biopharma. Read more 👉 https://lnkd.in/gUNjijjn #FasterForThePatient #innovation #biopharma #immunology

Congratulations to our portfolio company Noema Pharma for reaching a key clinical milestone in the treatment of Tourette Syndrome. 👏   In its Phase 2a clinical study, NOE-105 (gemlapodect) showed significant improvements for all patients, confirming its potential to offer a meaningful advancement in the treatment of Tourette syndrome. Today, over half a million individuals are suffering from Tourette Syndrome in the US alone, and millions worldwide.   Learn more about Noema's findings 👉 https://lnkd.in/gBatv5-H   #TouretteSyndrome #innovation #biopharma #clinicaltrial 

With robust growth and substantial value creation potential for patients, the biopharmaceutical sector stands out as one of the most promising to watch.   At #VCF24 organized by Invest Europe, Ksenija Pavletic, Partner at JEITO, outlined the market dynamics fueling this momentum:   ➡ The urgent need for new treatments, as two-thirds of known diseases still lack therapeutic options ➡ Big pharma Groups are approaching a patent cliff by 2030 and need to renew its innovation pipeline. At the same time, they are increasingly outsourcing R&D   In this environment, JEITO has developed a proven methodology, as demonstrated by our recent exits from EyeBio and HI-Bio: A Biogen Company, to accelerate the delivery of therapeutic innovations to patients. As Ksenija Pavletic emphasized, our approach is notably built on:   ➡ A rigorous selection process for scientific projects ➡ A multidisciplinary team that mirrors the highest standards of the pharmaceutical industry, ensuring the companies we support successfully navigate critical milestones, from clinical development to market access. ➡ A strategic refinancing approach that is essential for biopharma companies needing re-investment in continuity   We are grateful to Invest Europe for facilitating these valuable discussions!   #privateequity #lifesciences #biopharma #innovation #healthcare

We are thrilled to announce that JEITO has been selected to join the ILPA Summit, one of the most important private equity events worldwide.   Institutional Limited Partners Association (ILPA), the organization behind this prestigious event, is dedicated exclusively to the global Limited Partner community in private market.   Representing over 575 institutions and more than $2 trillion USD of private markets assets under management, ILPA’s members include public pensions, corporate pensions, endowments, foundations, family offices, insurance companies, and sovereign wealth funds located around the world.   Our participation highlights the relevance of our unique and differentiated investment strategy and our commitment to delivering value for patients and all our stakeholders. Attending ILPA? Our team will be there and happy to connect with you!   #ILPASummit24 #privateequity #investment #lifescience #biopharma

Meet the JEITO team in Amsterdam on September 25th and 26th at #VCF24, hosted by Invest Europe! 👋   🎤 Ksenija Pavletic, Partner at Jeito, will be taking the stage to discuss exit strategies with industry leaders Stefan Fällgren (Skandia) and Mitesh Pabari (Hamilton Lane), in a session moderated by Saman Sadeghi (Van Campen Liem).   How do current market conditions impact exit strategies and LP expectations? What strategies are LPs and GPs using to maximise exit value in a volatile market? 🤔 These key questions and more will be explored during the panel discussion.   Don’t miss out, register here 👉 https://lnkd.in/eCqDJMN5   #privateequity #lifesciences #biopharma

Sustainable innovation in healthcare starts with a deep understanding of the connections between all life forms on Earth 🌍   Human, animal, and plant health are inextricably linked! That's why, as a private equity fund committed to embedding sustainability into every step of our journey, we conducted our first #OneHealth workshop, a collaborative session to explore how these ecosystems are intertwined and how they impact our future.   Together, our team tackled some critical questions:   🌿 How does human activity drive biodiversity loss and the emergence of diseases? 🌡️ What role does climate change play in affecting these interdependent health systems? 💡 How we can overcome barriers and leverage opportunities to improve health outcomes for society?   This workshop is part of our broader sustainability training program, building on the strong foundations laid by our Climate Fresk initiative.   At JEITO, people are at the heart of everything we do. By deepening our understanding of our shared responsibility, we take the first steps toward creating a healthier, more sustainable future for all. 🌱   #sustainibility #ESG #privateequity #innovation #healthcare #environment #biodiversity #finance

Congratulations to CDR-Life Inc. teams for the First patient treated with its MAGE-A4-targeting T-cell engager CDR404. 👏   This is a major step achieved in the development of highly tumor-selective immunotherapies for patients suffering from solid tumors, including notably lung, head and neck cancer!   The first patient has been dosed as part of a Phase 1 study conducted by our portfolio company, at a time when there is an urgent need for new therapeutic solutions for these patients.   The trial, underway in both Europe and the U.S., is evaluating the safety, tolerability and preliminary anti-tumor activity of CDR404 in several common cancers including squamous cell carcinomas.   Read more about this new milestone 👉 https://lnkd.in/e2VQrW4X   #FasterForThePatient #innovation #immunotherapy #clinicaltrial #biopharma

We are very happy to see EyeBio, one of our portfolio companies acquired recently by Merck (MSD) for up to $3 billion, achieving a new major milestone!   In collaboration with Merck, the team has now initiated Phase 2b/3b clinical trials for Restoret in Diabetic Macular Edema (DME), right on schedule.   This significant progress highlights the strong potential of their pipeline in advancing treatments for back of the eye diseases.   Congratulations to all involved in this fantastic step! 👏   #innovation #biopharma #lifescience #ophthalmology https://lnkd.in/e2a5V9Ga

The Jeito team is back in action! 💼🚀 We're thrilled to attend IPEM for the 2024 edition, where we look forward to connecting with the key players driving private equity. Visit us at booth h209📍Our team is ready to meet you from September 9th to 11th. Let's discuss the future of innovation in healthcare and biopharma! See you there! #IPEM2024 #privateequity #finance #investment #lifescience #biopharma

We are very pleased to share that our portfolio company Noema Pharma announced the completion of enrollment in the GALENE Phase 2B trial evaluating the efficacy of NOE-101 for seizure control in Tuberous Sclerosis Complex (TSC)! 👏 TSC is a debilitating disease characterized by serious, life-threatening seizures with long-term impact on brain development and caused by mutations in the TSC1 and TSC2 genes. Approximately 80,000 people in the US and EU are diagnosed with TSC, and about 60 percent of patients do not respond to current treatment options. Congratulations to the Noema Pharma team for this new achievement! Read more 👉 https://lnkd.in/e-eCrMbm #FasterForThePatient #Innovation #Biopharma #RareDisease #NeuromuscularDisease